Once-Yearly Histrelin Subdermal Implant Provides Long-Term Efficacy In Prostate Cancer Patients
Links shared publicly online about this topic.
- 1,226total visits
Once-Yearly Histrelin Subdermal Implant Provides Long-Term Efficacy In Prostate Cancer Patients
BARCELONA - The luteinizing hormone- releasing hormone (LHRH) agonist histrelin acetate (VantasR), a subcutaneous implant replaced once yearly, maintains testosterone suppression over four years
View full resource at medicalnewstoday.com
Tags: Hormone, Cancer, Prostate Cancer, Prostate, Men's Health
Most Recently Shared on April 21, 2010 at 10:15 am By:
Once-Yearly Histrelin Subdermal Implant Provides Long-Term Efficacy In Prostate Cancer Patients http://mnt.to/3Bwy #cancer
Also Shared By:
Advertisement
MNT Health News
@mnt_healthnews
Once-Yearly Histrelin Subdermal Implant Provides Long-Term Efficacy In Prostate Cancer Patients http://mnt.to/3Bwy #healthnews
1 year ago...